Loading
A phase 1/2 trial of Pembrolizumab in renal cell carcinoma and non-small-cell lung cancer, run by Medicenna Therapeutics, Inc., now recruiting.
A Beta-only IL-2 ImmunoTherapY Study is a phase 1/2 interventional study registered as NCT05086692 by Medicenna Therapeutics, Inc., with 115 participants planned, started 2021-08-27 and due to reach its primary completion in 2026-06-30. Interventions recorded: MDNA11, Pembrolizumab (KEYTRUDA®). Conditions listed: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Pembrolizumab, Immune checkpoint inhibitors.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Pembrolizumab.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Pembrolizumab.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Non-small-cell lung cancer.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Immune checkpoint inhibitors.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Pembrolizumab.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Pembrolizumab, Immune checkpoint inhibitors.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/